自1978年，改革开放30余年，中国经济突飞猛进的发展。在经济全球化的背景下，随着中国综合实力的提高，中国企业的国际化步伐也是越来越快。 中国企业的国际化也就是我们常说的“走出去”，是中国从经济发展全局出发作出的重大战略决策，对推动中国经济的转型升级、拓展我国经济发展空间、提高国际竞争水平、促进可持续发展进程具有重要意义。 “走出去”的战略不仅可以使企业开发新的国际市场、增加出口额，而且可增强中国企业在国际上的影响力，进而引导或参与国际化经济合作。 有着近六十年历史积淀的桂林南药股份有限公司（桂林南药）是具有我国自主知识产权的抗疟药“青蒿琥酯”的原研厂家，也是我国最大的抗疟药生产商之一，其注射用青蒿琥酯等5个品种已在近40个国家取得401张药品注册证，自2005年开始国际化战略，出口额一年比一年高，2014年的出口额实现4600万美元，位列中国医药保健品进出口商会权威发布《2014年西药原料药、西成药、生化药出口20强企业名单》9强，可以说桂林南药开拓了一条属于自己的国际化道路。本文以企业国际化相关理论为依据，通过案例分析的方法，以桂林南药作为研究对象，对其国际化战略进行深入分析，总结其国际化的成功经验和存在的问题，为桂林南药的国际化之路提出建议，为企业管理者提供参考，并且为中国正在和即将国际化的制药企业提供一个具有代表性、可以参考的企业国际化案例，以期使得中国企业在国际化道路上少些弯路。本文第一章国内外的经济环境以及医药产业发展情况的背景，介绍论文的选题背景，研究意义及其方法；其次第二章介绍了企业国际化的相关理论，作为本文的理论基础。第三章通过对桂林南药国际化经营背景的阐述，发现桂林南药应势而生的国际化之路，根据其出口额总结其国际化历程。第四章分析了桂林南药国际化战略环境。第五章主要介绍桂林南药的国际化战略。第六章分析了桂林南药国际化进程存在的问题，以及解决这些问题的对策建议。最后，第七章总结桂林南药国际化的成功经验和挑战，从而为中国医药企业国际化提供参考和帮助。

Since 1978, more than 30 years of reform and opening up, China's economic development by leaps and bounds. Under the background of economic globalization, With the improvement of China's comprehensive strength, the internationalization of Chinese enterprises pace is faster and faster. The internationalization of Chinese enterprises, that is, we often say \"go out\", is China's important strategic decisions made from the global economic development, to promote the transformation and upgrading of China's economy, expand the economic development of our country space, improve the level of international competition, promote the sustainable development is of great significance. \"Going out\" strategy can not only make the enterprise develop new international market, increase exports, but also can enhance Chinese enterprises in international influence, lead or participate in international economic cooperation. With nearly 60 years history of guilin pharmaceutical co., LTD. (guilin pharma) is a China's independent intellectual property rights of antimalarial drugs of artesunate, original manufacturer is also one of China's largest producer of antimalarial drugs, and its injection with artesunate and other five varieties have 401 pieces of drug registration in nearly 40 countries, since 2005 the internationalization strategy, high exports year after year, exports of $2014 in 46 million, in Chinese medicine and health products import and export chamber of commerce authority released the 2014 API, the western medicine, western medicine biochemical medicine export list of top 20 enterprises 9 is strong, can say guilin pharmaceutical opens up a path to a belongs to own internationalization. In this paper, based on enterprise internationalization theory, through the case analysis method, to guilin pharmaceutical as the research object, analyzing the internationalization strategy, summed up the international successful experiences and existing problems, and gives Suggestions for the road of the internationalization of guilin pharmaceutical, provides the reference for enterprise managers, and the international pharmaceutical industry of China is and will provide a representative case, can refer to enterprises internationalization, in order to make less detours on the road to the internationalisation of Chinese enterprises. This article first chapter economic environment both at home and abroad as well as the background of the development of medicine industry, introduced the paper selected topic background, research significance and methods; The second chapter introduces the relevant theories of enterprise internationalization, as a theoretical basis for this article. The third chapter through to guilin pharmaceutical international operation background, should find guilin pharmaceutical potential of the road of internationalization, according to its exports, summarizes its internationalization process. The fourth chapter analyzes the guilin pharmaceutical international strategy environment. The fifth chapter mainly introduces the guilin pharmaceutical internationalization strategy. The sixth chapter analyzes the problems of guilin pharmaceutical internationalization, as well as the countermeasures and Suggestions to solve these problems. Finally, chapter seven summarizes the successful experience of guilin pharmaceutical internationalization and challenges, so as to provide reference for Chinese pharmaceutical enterprises internationalization and help.